Table 3 Subgroup analyses of efficacy and safety of thrombolysis for acute IS with AF based on study design

Retrospective(n = 6)

250/886

990/2777

0.68 (0.57–0.81)

< 0.001

75.0

0.006

Prospective(n = 4)

101/568

782/2358

0.41 (0.32–0.52)

< 0.001

0.0

0.343

IVT

Non-IVT

OR (95% CI)

P

I² (%)

P

Retrospective(n = 4)

238/859

272/1183

1.24 (1.01–1.52)

0.039

74.5

0.008

Prospective(n = 3)

65/403

409/2004

0.65 (0.48–0.87)

0.005

92.1

< 0.001

AF

Non-AF

OR (95% CI)

P

I² (%)

P

Retrospective(n = 8)

363/976

1523/2962

0.53 (0.46–0.62)

< 0.001

63.2

0.008

Prospective(n = 3)

138/515

848/1993

0.44 (0.35–0.55)

< 0.001

0

0.474

IVT

Non-IVT

OR (95% CI)

P

I² (%)

P

Retrospective(n = 4)

302/859

382/1183

1.10 (0.91–1.33)

0.317

50.6

0.108

Prospective(n = 2)

73/350

636/1949

0.53 (0.40–0.70)

< 0.001

96.7

< 0.001

AF

Non-AF

OR (95% CI)

P

I² (%)

P

Retrospective(n = 8)

204/1044

378/3047

1.86 (1.54–2.25)

< 0.001

49.7

0.053

Prospective(n = 6)

189/983

329/3089

2.30 (1.88–2.82)

< 0.001

25.7

0.242

IVT

Non-IVT

OR (95% CI)

P

I² (%)

P

Retrospective(n = 4)

183/859

272/1183

0.91 (0.74–1.13)

0.413

0.0

0.998

Prospective(n = 3)

100/403

387/2004

1.34 (1.04–1.73)

0.025

86.3

0.001

AF

Non-AF

OR (95% CI)

P

I² (%)

P

Retrospective(n = 8)

48/1026

71/3022

1.67 (1.14–2.46)

0.009

0

0.490

Prospective(n = 5)

78/939

178/3048

1.56 (1.17–2.07)

0.002

0

0.509

IVT

Non-IVT

OR (95% CI)

P

I² (%)

P

Retrospective(n = 4)

43/857

14/1183

4.04 (2.16–7.55)

< 0.001

0.0

0.566

Prospective(n = 2)

11/87

8/152

2.18 (0.80–5.88)

0.126

0.0

0.592